MRTX1133
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
MRTX1133 is an investigational drug that targets the G12D mutation in KRAS dependent cancers. MRTX1133 was in a phase 1/2 clinical trial for the treatment of solid tumors, however the study was terminated in Q1 2025. MRTX1133 is considered to be harmful from direct skin or eye exposure other than transient irritation. It may cause irritation of the respiratory system if inhaled.
MRTX1133 is an investigational drug that targets the G12D mutation in KRAS dependent cancers. MRTX1133 was in a phase 1/2 clinical trial for the treatment of solid tumors, however the study was terminated in Q1 2025. MRTX1133 is considered to be harmful from direct skin or eye exposure other than transient irritation. It may cause irritation of the respiratory system if inhaled.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372759927 under CC BY-SA 4.0; modifications have been made.